Table 4.

Comparison of immune responses to PCV13 versus PCV7 among toddlers

Study	Kieninger et al. [40]							Yeh et al. [41]
Country (year)	Germany (2010)							USA (2010)
Dosing schedule	1 dose (11–12 months)							1 dose (12–15 months)
Vaccine	PCV7				PCV13			PCV7				PCV13
Immunogenicity	OPA titer		ELISA (IgG, μg/mL)		OPA titer		ELISA (IgG, μg/mL)	OPA titer		ELISA (IgG, μg/mL)		OPA titer		ELISA (IgG, μg/mL)
	GMT	≥1:8 (%)	GMC	≥0.35 (%)	GMT	≥1:8 (%)	GMC	GMT	≥1:8 (%)	GMC	≥0.35 (%)	GMT	≥1:8 (%)	GMC	≥0.35 (%)
PCV7 serotypes
4	2,885	100		5.07	2,491	100	4.16	1,492	98.9		5.49	1,180	98.9		3.73
6B	2,907	98.9		9.85	2,687	100	9.14	4,066	100		15.63	3,100	98.9		11.53
9V	16,026	100		3.36	13,704	100	2.75	18,032	100		3.63	11,856	98.9		2.62
14	4,925	100		11.01	3,012	100	8.34	2,366	100		12.72	2,002	100		9.11
18C	1,762	100		3.44	1,326	100	2.79	1,722	100		4.70	993	98.9		3.20
19F	265	94.8		4.72	345	99.0	5.99	167	94.8		5.60	200	96.7		6.60
23F	3,738	95.6		4.33	2,854	97.9	3.36	4,982	100		7.84	2,723	98.9		5.07
Other serotypes
1	5	15.8		0.03	198	99.0	4.25	5	12.0		0.03	164	98.9		5.06
3	8	35.8		0.07	188	98.0	1.02	12	43.8		0.07	380	97.8		0.94
5	4	2.2		0.51	327	99.0	3.56	5	5.2		0.55	300	98.9		3.72
6A	501	92.5		1.74	2,502	99.0	5.88	539	94.8		1.87	2,242	98.9		8.20
7F	182	85.2		0.05	10,213	100	4.79	268	80.4		0.05	11,629	100		5.67
19A	59	68.1		3.79	1,349	100	9.58	268	53.2		3.54	1,024	97.8		8.55

OPA, opsonophagocytosis assay; GMC, geometric mean concentration; GMT, geometric mean titer (calculated from the reciprocal of the individual titers)